Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian W Dymock

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Nature Communications|December 21, 2017
Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethalityMayumi Kitagawa, Pei-Ju Liao, Kyung Hee Lee, et al.
Bioorganic & Medicinal Chemistry Letters|February 8, 2008
Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivityMonika Ermann, Doris Riether, Edward R Walker, et al.
Journal of Medicinal Chemistry|May 25, 2011
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphomaAnthony D William, Angeline C-H Lee, Stéphanie Blanchard, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2008
DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activityStephen P East, Clara Bantry White, Oliver Barker, et al.
Journal of Medicinal Chemistry|June 4, 2011
Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profileHaishan Wang, Niefang Yu, Dizhong Chen, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Nature Communications|December 21, 2017
Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethalityMayumi Kitagawa, Pei-Ju Liao, Kyung Hee Lee, et al.
Bioorganic & Medicinal Chemistry Letters|February 8, 2008
Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivityMonika Ermann, Doris Riether, Edward R Walker, et al.
Journal of Medicinal Chemistry|May 25, 2011
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphomaAnthony D William, Angeline C-H Lee, Stéphanie Blanchard, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2008
DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activityStephen P East, Clara Bantry White, Oliver Barker, et al.
Journal of Medicinal Chemistry|June 4, 2011
Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profileHaishan Wang, Niefang Yu, Dizhong Chen, et al.
Pageof 5